Observational studyBMC cardiovascular disorders2025
The plasma lipopolysaccharide level is associated with contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLipopolysaccharide (LPS) plays an important role in cardiovascular and renal diseases. However, the relationship between LPS and contrast-induced acute kidney injury (CI-AKI) remains unclear. This study aimed to investigate the role of LPS in patients with ST-segment elevation myocardial infarction (STEMI) and its relationship with CI-AKI following percutaneous coronary intervention (PCI).
methodsThis single-centre retrospective observational study included 710 patients diagnosed with STEMI. CI-AKI was defined as an increase in SCr of at least 50% or 0.3 mg/dL within 48-72 h after contrast exposure. Regression analysis was used to identify potential risk factors. Restricted cubic splines (RCSs) were used to explore the dose‒response relationship between LPS levels and CI-AKI. The models were evaluated using receiver operating characteristic (ROC) curves, the net reclassification index (NRI), and the integrated discrimination improvement (IDI) index.
resultsThe incidence of CI-AKI during hospitalization was 12.5%. After adjusting for potential confounding factors, the results revealed that LPS (OR = 0.650, 95% CI: 0.466-0.906) was an independent risk factor that affected the occurrence of CI-AKI. The RCS results revealed a linear dose‒response relationship between LPS and CI-AKI. After integration of LPS, the model demonstrated a significantly improved ability to predict CI-AKI (IDI 0.095, P < 0.001; NRI 0.720, P < 0.001).
conclusionElevated LPS is an independent risk factor for the development of CI-AKI after PCI in patients with STEMI. The integration of LPS detection significantly improved the risk model for CI-AKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.